Relenza growth and expansion plans lift Biota
This article was originally published in Scrip
Executive Summary
Biota Holdings has been buoyed by a more than doubling in royalty payments received from GlaxoSmithKline for Relenza (zanamivir), along with news that the UK firm will triple its production of the inhaled neuraminidase inhibitor by the end of the year.